USPTO Agrees to Kurin’s Request to Review Validity of Magnolia Medical’s ‘483 Patent

Kurin, Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, announced today that the US Patent and Trademark Office has granted Kurin’s Ex Parte request to reexamine the validity of U.S. Patent No. 10,039,483 (the ‘483 patent) that is asserted by Magnolia Medical in ongoing patent litigation. The Examiner noted there were multiple “Substantial New Questions of Patentability” that merit review.

“We are pleased that the Examiner has agreed to the review of the patentability of the relevant claims in the ‘483 patent” said Bob Rogers, CEO of Kurin, Inc. “Magnolia originally asserted four patents, then dropped the others leaving just the ‘483 patent for trial. The prior art that was not previously considered raises serious questions about the validity of the ‘483 patent and would therefore have significant impact on Magnolia’s efforts to prevent access to the Kurin Lock.”

“We look forward to the resolution of this matter. We continue to believe this litigation was a bullying attempt by Magnolia to try to address its inability to compete fairly with the smaller and more user-friendly Kurin device.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections.

USPTO Ex Parte Reexamination Communication

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.